Sputnik V receives DCGI approval, makes it 3rd corona vaccine for India

The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

India on Monday approved Russian jab Sputnik V as the third Covid-19 vaccine for restricted use in the country. The vaccine was developed by the Gamaleya Research Institute (GRI) of Russia, and funded and promoted outside by the Russian Direct Investment Fund (RDIF).

In India, the RDIF's partner is Dr Reddy's Laboratories, which conducted clinical trials - mandatory for approval - India. Sputnik-V became the first vaccine to be announced last year for protection against Covid-19.

It works on complex biotechnology in which another virus is employed to carry the DNA code required for triggering an immune response in human cells. Sputnik V's approval has come at a time when the country is reeling under a shortage of existing two vaccines - Covishield and Covaxin.

India has a combined production capacity of around 6.40 crore doses a month of the two approved vaccines in a month. Covishield-maker Serum Institute of India (SII) is shouldering the major burden as the other vaccine-manufacturer, the Bharat Biotech has a limited capacity of 40 lakh doses a month.

Several states have flagged in recent days that both Covishield and Covaxin are in short supply. Reports of vaccination centres from Varanasi in Uttar Pradesh to Mumbai in Maharashtra appeared last week.

Vaccine shortage became an issue of a political fight between the Centre and the Opposition-ruled governments in the backdrop of the second wave of Covid-19 pandemic wreaking havoc in at least 10 states. Maharashtra, Delhi, Chhattisgarh, Punjab, Madhya Pradesh, Kerala, and Uttar Pradesh are among severely impacted states.

The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

Sputnik V, named after the first Soviet space satellite, showed a better efficacy during trials compared to the vaccines already in use in India. Both Covishield and Covaxin showed the efficacy of around 81 per cent in the trials, Sputnik V returned with 91-92 per cent efficacy.

On the production front, the Russian Direct Investment Fund (RDIF) has tied up with Indian pharmaceutical firms such as Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the manufacturing the vaccine doses.

These firms jointly have an annual production capacity of 850 million doses for Sputnik V. This makes Sputnik V's approval a big shot in the arm in the fight against the Covid-19 pandemic.

It is expected that the doses of the Sputnik V vaccine will be available at vaccination centres by June this year. There are at least four more vaccines that are expected to get approval from the Drug Controller General of India (DCGI) by the year-end.







Tags : #SputnikV #RussianVaccineforCorona #EfficacyofRussianVaccine #DrReddysLab #SerumInstituteofIndia #BharatBiotech #DCGI #LatestNewsonCOVIDVaccine13thApr

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Moscow Researchers Develop Russia's Pioneer Lumbosacral Spine Phantom for Anesthesia Ultrasound TrainingNovember 12, 2024
World Pneumonia Day: How Pneumonia Continues to Steal Lives and What We Can Do About ItNovember 12, 2024
From Darkness to Clarity: How Stem Cell Transplants Are Offering New Hope for Corneal BlindnessNovember 12, 2024
Daytime Sleepiness and Dementia: Is Napping in the Afternoon Putting You at Risk?November 12, 2024
GET WEDDING-READY WITH KAY BEAUTY: KATRINA KAIF’S TOP PICKS FOR BRIDES & BRIDESMAIDSNovember 11, 2024
Amrita Vishwa Vidyapeetham Students Win Global All-Track Grand Prize at HackHarvard 2024 Organized by Harvard University StudentsNovember 11, 2024
Algorand Foundation Announces its Investment in 5 Startups from the Inaugural Startup Lab Program at T-HubNovember 11, 2024
DOST, DTI & DICT join forces for Philippine Startup Week 2024 to Ignite Filipino InnovationNovember 11, 2024
Firewall gender equality from threats like anti-rights Geneva Consensus DeclarationNovember 11, 2024
Delhi’s Air Crisis: How Toxic Air and Pollution Are Still Threatening Health and Life QualityNovember 11, 2024
Are You at Risk? AI Data Exposes Unseen Triggers of Diabetes in Our EnvironmentNovember 11, 2024
Why Children in High-Risk Areas Are Paying the Price for TB Neglect?November 11, 2024
The Deadly 17: WHO’s Vaccine Priority List to Tackle Life-Threatening InfectionsNovember 09, 2024
Is Your Gut Telling You Something? The Bacterial Clues to Early Rheumatoid ArthritisNovember 09, 2024
Newcastle University Announces VC Excellence Scholarships for Undergraduate and Postgraduate StudiesNovember 08, 2024
Beyond the X-ray: Celebrating the Pioneers of Radiography on World Radiography DayNovember 08, 2024
Digital Doctors and Village Heroes: Tackling Depression and Stigma in India’s HeartlandNovember 08, 2024
Why Are Food Giants Pushing ‘Low-Star’ Nutrition on Low-Income Countries?November 08, 2024
NokAir joins hands with Çelebi for world class ground handling services for newly launched Bangkok-Mumbai routeNovember 07, 2024
Why Are Rare Disease Patients Paying a Fortune When Local Production Could Save Lives?November 07, 2024